Graham Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Graham Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-321,837	Closed	-$135K	–	1465
2025 Q4	$135K	Buy	321,837 +56,656	+21%	+$30K	﹤0.01%	1117
2025 Q3	$179K	Buy	+265,181	New	+$143K	﹤0.01%	1082
2025 Q2	–	Sell	-431,766	Closed	-$283K	–	1587
2025 Q1	$283K	Buy	431,766 +338,591	+363%	+$359K	0.01%	1015
2024 Q4	$95K	Sell	93,175 -62,967	-40%	-$115K	﹤0.01%	1163
2024 Q3	$135K	Buy	+156,142	New	+$114K	﹤0.01%	977
2023 Q4	–	Sell	-96,102	Closed	-$57.6K	–	1300
2023 Q3	$57.6K	Buy	96,102 +28,354	+42%	+$30.4K	﹤0.01%	962
2023 Q2	$88.1K	Buy	+67,748	New	+$92.6K	﹤0.01%	898
2022 Q3	–	Sell	-311,960	Closed	-$1.29M	–	1294
2022 Q2	$1.29M	Buy	+311,960	New	+$1.35M	0.05%	350

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Graham Capital Management's SGMO Position: Q1 2026 in Review

Graham Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 321,837 shares — an estimated $135K sold.

Graham Capital Management first reported a position in SGMO in Q2 2022 and held it in 8 quarters. The position peaked at $1.29M in Q2 2022. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

Graham Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 321,837 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $135K.
Graham Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2022 and held it in 8 quarters.
Graham Capital Management's SANGAMO THERAPEUTICS INC position peaked at $1.29M in Q2 2022.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.